Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SinoMab BioScience Limited
  6. News
  7. Summary
    3681   HK0000544194

SINOMAB BIOSCIENCE LIMITED

(3681)
  Report
SummaryChartsNewsCalendarCompanyFinancials 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about SINOMAB BIOSCIENCE LIMITED
01/11SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of ..
AQ
2021SinoMab BioScience Grants Restricted Share Units to Director
MT
2021SinoMab BioScience Limited Appoints Lei SHI as Non-Executive Director
CI
2021SinoMab BioScience Limited Announces Change of Non-Executive Directors
CI
2021SinoMab BioScience Completes Patient Enrollment for China Phase 3 Study of Arthritis Dr..
MT
2021SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for..
AQ
2021SinoMab BioScience Limited Announces SM03 ?Completion of Enrollment in Phase III Clinic..
CI
2021SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
AQ
2021SINOMAB BIOSCIENCE : (i) CONNECTED TRANSACTION UNDER THE SUPPLEMENTAL AGREEMENT TO THE BTK..
PU
2021SINOMAB BIOSCIENCE : Sinovent and Everest Medicines Announce Licensing Agreement for Globa..
AQ
2021Everest Medicines, Suzhou Sinovent Pharmaceuticals Co. Ltd. and SinoMab BioScience Limi..
CI
2021SINOMAB BIOSCIENCE : Widens Losses in H1
MT
2021Sinomab Bioscience Limited Reports Earnings Results for the Half Year Ended June 30, 20..
CI
2021SINOMAB BIOSCIENCE : China Authorizes SinoMab's Lupus Drug as Treatment for Another Autoim..
MT
2021SINOMAB BIOSCIENCE : $13 Million Bond Issuance Deal with Potential Investor Falls Through
MT
More most relevant news
All news about SINOMAB BIOSCIENCE LIMITED
01/11SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of ..
AQ
2021SinoMab BioScience Grants Restricted Share Units to Director
MT
2021SinoMab BioScience Limited Appoints Lei SHI as Non-Executive Director
CI
2021SinoMab BioScience Limited Announces Change of Non-Executive Directors
CI
2021SinoMab BioScience Completes Patient Enrollment for China Phase 3 Study of Arthritis Dr..
MT
2021SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for..
AQ
2021SinoMab BioScience Limited Announces SM03 ?Completion of Enrollment in Phase III Clinic..
CI
2021SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
AQ
2021SINOMAB BIOSCIENCE : (i) CONNECTED TRANSACTION UNDER THE SUPPLEMENTAL AGREEMENT TO THE BTK..
PU
2021EVEREST MEDICINES : Wins License to Kidney Disease Treatment; Shares Rise 4%
MT
More news
News in other languages on SINOMAB BIOSCIENCE LIMITED
2021SinoMab BioScience octroie des unités d'actions restreintes à un directeur
2021SinoMab BioScience creuse ses pertes au premier semestre
2021La Chine autorise l'utilisation du médicament de SinoMab contre le lupus pour traiter u..
2021L'accord d'émission d'obligations de 13 millions de dollars de SinoMab Bioscience avec ..
More news
Press releases
01/11SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of ..
AQ
2021SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for..
AQ
2021SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
AQ
2021SINOMAB BIOSCIENCE : (i) CONNECTED TRANSACTION UNDER THE SUPPLEMENTAL AGREEMENT TO THE BTK..
PU
2021SINOMAB BIOSCIENCE : Sinovent and Everest Medicines Announce Licensing Agreement for Globa..
AQ
More press releases
Upcoming event on SINOMAB BIOSCIENCE LIMITED